Literatur
-
1
Greten T F, Blum H E, Manns M P. et al .
Therapie des hepatozellulären Karzinoms.
Z Gastroenterol.
2006;
44
43-49
-
2
Burroughs A, Hochhauser D, Meyer T.
Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.
Lancet Oncol.
2004;
5
409-418
-
3
Yeo W, Mok T S, Zee B. et al .
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
J Natl Cancer Inst.
2005;
97
1532-1538
-
4
Becker G, Allgaier H P, Olschewski M. et al .
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Hepatology.
2007;
45
9-15
-
5
Thomas M B, Abbruzzese J L.
Opportunities for targeted therapies in hepatocellular carcinoma.
J Clin Oncol.
2005;
23
8093-8108
-
6
Ito Y, Sasaki Y, Horimoto M. et al .
Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma.
Hepatology.
1998;
27
951-958
-
7
Calvisi D F, Ladu S, Gorden A. et al .
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Gastroenterology.
2006;
130
1117-1128
-
8
Yoshida T, Hisamoto T, Akiba J. et al .
Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
Oncogene.
2006;
25
6056-6066
-
9
Kane R C, Farrell A T, Saber H. et al .
Sorafenib for the treatment of advanced renal cell carcinoma.
Clin Cancer Res.
2006;
12
7271-7278
-
10
Philip P A, Mahoney M R, Allmer C. et al .
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
J Clin Oncol.
2005;
23
6657-6663
-
11
Zhu A X, Blaszkowsky L S, Ryan D P. et al .
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
J Clin Oncol.
2006;
24
1898-1903
PD Dr. med. Jörg Trojan
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt a. M.
Medizinische Klinik I
Theodor-Stern-Kai 7
60590 Frankfurt
eMail: trojan@em.uni-frankfurt.de
